semaglutide vs tirzepatide for inflammation vs. Weight Loss Comparative safety and side effects

more recently FDA approved drugs in this category include baricitinib (Olumiant ) & upadacitinib (Rinvoq )

Developed by Novo Nordisk, WEGOVY (semaglutide) is a GLP-1 receptor agonist designed to support sustainable weight loss when paired with a balanced diet and regular physical activity

This is an appropriate option after a patient has not achieved relief using nonpharmacologic measures and bulk-forming laxatives

Now, a new study recently published in the journal Nature Medicine reports that taking GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered dementia and addiction risks

July 25, 2024: The number of GLP-1 lawsuits in the federal MDL increased to 105 cases

Decisions of that kind should be made with your medical team, informed by your individual circumstances